ClinicalTrials.gg
RecruitingNCT06523751Updated Apr 3, 2025

Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy

An interventional study of Trabeculopuncture in Open Angle Glaucoma and Pseudoexfoliation Glaucoma, sponsored by Wuerzburg University Hospital. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Wuerzburg University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2023, registered Jul 2024).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Glaucoma, Open-Angle with a site in Germany — 7 open to participants now, 11 under way, none of them phase 3. Glaucoma, Open-Angle · Germany.

Planned enrollment
25th of 46
55 · median 60
Started
2023
with 4 others
No phase
22 of 64
5 open now
Primary completion
2025-12
later than 0 of 10 live
Registered
62nd of 64
by date

Among the 64 studies in Glaucoma, Open-Angle with a site in Germany, this one is the 25th largest by planned enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2023, is one of 22 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 62nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 64 studies in Glaucoma, Open-Angle with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Glaucoma, Open-Angle with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to perform trabeculopuncture a test to determine the distal outflow tract function to predict the success of ab interno trabeculectomy.

Read the detailed description

The aim of this study is to develop a non-invasive predictive test for the function of the distal outflow tract after ab interno trabeculectomy for open angle glaucoma. We hypothesize that the ocular pressure drop and outflow change after preoperative trabeculectomy may predict the success of ab interno trabeculectomy. The results of this study should allow trabeculopuncture to be used to select the most appropriate procedure for the individual patient.

03

Conditions studied

  • Open Angle Glaucoma
  • Pseudoexfoliation Glaucoma

Keywords

  • Ab Interno Trabeculectomy
  • Trabeculopuncture
  • Open Angle Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals ≥ 18 years of age
  • clinical diagnosis of: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma
  • uncontrolled intraocular pressure (IOP) with maximally tolerated medical therapy
  • progressive thinning of retinal nerve fiber layer assessed by Spectral domain optical coherence tomography (p \< 0.05)
  • progression of visual field defects
  • visually significant cataract and indication to reduce IOP or glaucoma medication burden

Exclusion criteria

Exclusion Criteria:

  • clinical diagnosis of neovascular glaucoma, angle-closure glaucoma, uveitic glaucoma, neovascular glaucoma
  • prior glaucoma surgery
  • preexisting conditions affecting the episcleral venous pressure including Grave's ophthalmopathy, Sturge-Weber syndrome, Arteriovenous fistulas (carotid-cavernous fistula)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Trabeculopuncture

    Individuals undergo neodymium-doped yttrium aluminum garnet (Nd:YAG) trabeculopuncture prior to ab interno trabeculectomy.

    Diagnostic Test: Trabeculopuncture

Interventions

  • Diagnostic testTrabeculopuncture

    Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.

06

What researchers measure

Primary outcomes

  1. IOP

    Intraocular pressure measured by Goldmann applanation tonometry

    Time frame: before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively

  2. Outflow facility

    Outflow facility is measured by the use of a pneumatonometer

    Time frame: before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively

  3. Surgical success

    surgical success at month three is defined as 20% IOP reduction without increasing the number of glaucoma drops

    Time frame: at month three

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Verma-Fuehring R, Dakroub M, Han H, Hillenkamp J, Loewen NA. Trabeculopuncture as a predictive test of distal outflow resistance in canal-based surgery. Sci Rep. 2022 Jun 22;12(1):10584. doi: 10.1038/s41598-022-13990-9. PubMed 35732782 ↗
  • Epstein DL, Melamed S, Puliafto CA, Steinert RF. Neodymium: YAG laser trabeculopuncture in open-angle glaucoma. Ophthalmology. 1985 Jul;92(7):931-7. doi: 10.1016/s0161-6420(85)33932-5. PubMed 4022580 ↗
  • Melamed S, Pei J, Puliafito CA, Epstein DL. Q-switched neodymium-YAG laser trabeculopuncture in monkeys. Arch Ophthalmol. 1985 Jan;103(1):129-33. doi: 10.1001/archopht.1985.01050010135037. PubMed 3977666 ↗
  • Del Priore LV, Robin AL, Pollack IP. Long-term follow-up of neodymium: YAG laser angle surgery for open-angle glaucoma. Ophthalmology. 1988 Feb;95(2):277-81. doi: 10.1016/s0161-6420(88)33195-7. PubMed 3173993 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2025, 30 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 30 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 26, 2024
StartActual
Jun 13, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 31, 2026
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06523751
Lead sponsor
Wuerzburg University Hospital
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Jun 13, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Apr 3, 2025

Study contacts

Raoul Verma-Fuehring, MD
Contact
vermafuehr_R@ukw.de
+49 93120120662
Daniel Kampik, MD, PhD
principal investigator · Department of Ophthalmology University Hospital Würzburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion